Allergan PLC. (NYSE:AGN) Director Christopher J. Coughlin bought 10,000 shares of the firm’s stock in a transaction dated Tuesday, December 5th. The shares were acquired at an average price of $163.30 per share, with a total value of $1,633,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Allergan PLC. (NYSE AGN) opened at $164.87 on Friday. Allergan PLC. has a 52 week low of $160.07 and a 52 week high of $256.80. The company has a quick ratio of 1.08, a current ratio of 1.18 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $54,636.75, a PE ratio of 10.65, a price-to-earnings-growth ratio of 1.10 and a beta of 1.11.

Allergan (NYSE:AGN) last posted its earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.06 by $0.09. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The company had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same quarter in the previous year, the firm earned $3.32 earnings per share. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. equities research analysts expect that Allergan PLC. will post 16.28 EPS for the current fiscal year.

Allergan declared that its board has initiated a stock repurchase plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the company to buy up to 2.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board of directors believes its shares are undervalued.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 15th. Shareholders of record on Friday, November 17th will be paid a $0.70 dividend. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $2.80 annualized dividend and a yield of 1.70%. Allergan’s dividend payout ratio (DPR) is presently -12.44%.

A number of institutional investors and hedge funds have recently bought and sold shares of AGN. Hudock Capital Group LLC grew its stake in shares of Allergan by 0.4% during the second quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock worth $138,000 after acquiring an additional 2 shares during the last quarter. Burns J W & Co. Inc. NY grew its stake in shares of Allergan by 0.7% during the second quarter. Burns J W & Co. Inc. NY now owns 906 shares of the company’s stock worth $220,000 after acquiring an additional 6 shares during the last quarter. Pacific Center for Financial Services grew its stake in shares of Allergan by 1.3% during the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after acquiring an additional 7 shares during the last quarter. Gilder Gagnon Howe & Co. LLC grew its stake in shares of Allergan by 0.5% during the second quarter. Gilder Gagnon Howe & Co. LLC now owns 1,666 shares of the company’s stock worth $405,000 after acquiring an additional 9 shares during the last quarter. Finally, Trust Co grew its stake in shares of Allergan by 0.8% during the first quarter. Trust Co now owns 1,224 shares of the company’s stock worth $292,000 after acquiring an additional 10 shares during the last quarter. Institutional investors own 81.34% of the company’s stock.

Several analysts have recently weighed in on AGN shares. Argus reiterated a “buy” rating and set a $280.00 target price on shares of Allergan in a research report on Monday, August 14th. BidaskClub downgraded Allergan from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Cantor Fitzgerald reiterated a “hold” rating on shares of Allergan in a research report on Tuesday, August 22nd. Cowen reiterated an “outperform” rating and set a $400.00 target price on shares of Allergan in a research report on Tuesday, August 29th. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $285.00 target price on shares of Allergan in a research report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $235.25.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/08/allergan-plc-agn-director-buys-1633000-00-in-stock.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.